A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

Paper

A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

Published 2012 · Harriet, Bryson, B. Fulton

UNKNOWN SJR score

167

Citations

1

Influential Citations

Semantic Scholar

Abstract

Various sections of the manuscript reviewed by: H. Askmark, Department of Neurology, Uinssjukhuset, Halmstad, Sweden; O. Blin, Centre de Pharmacologie Clinique et d'Evaluations Therapeutiques, Hopital de la Timone, Marseilles, France; P. Drapeau, Montreal General Hospital Research Institute, Montreal, Quebec, Canada; P.N. Leigh, Department of Neurology, Institute of Psychiatry, London, England; V. Meininger, Service de Neurologie, Division Mazarin, Hopital de la Salpetriere, Paris, France; R.G. Miller, Department of Neurology, California Pacific Medical Center, San Francisco, California, USA; K. W. Muir, Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, Scotland; J.v. Nadler, Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, USA; R.w. Orrell, Neuromuscular Unit, Regional Centre and University Department of Clinical Neuroscience, Charing Cross Hospital, London, England; A. Plaitakis, Mount Sinai School of Medicine, New York, New York, USA; M. Umemiya, Department of Neurophysiology, Tohoku University School of Medicine, Sendai, Japan; M. Yasui, Division of Neurological Diseases, Wakayama Medical College, Wakayama, Japan.

Highly Cited

Study Snapshot

This review explores the pharmacodynamic and pharmacokinetic properties of a potential treatment for Amyotrophic Lateral Sclerosis, highlighting its therapeutic potential.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

Sign up to use Study Snapshot

References

Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis

Spontaneous amyotrophic lateral sclerosis is difficult to distinguish from familial amyotrophic lateral sclerosis, affecting neurogenetic advice for family members.

Glutamate Antagonists in Amyotrophic Lateral Sclerosis

Glutamate antagonists show potential in prolonging survival in ALS patients by decreasing excitatory transmission and modulating presynaptic glutamatergic mechanisms.

Dose-ranging study of riluzole in amyotrophic lateral sclerosis

The 100 mg dose of riluzole has the best benefit-to-risk ratio and prolongs survival in ALS patients, with common adverse reactions being asthenia, dizziness, gastrointestinal disorders, and rises in liver enzyme activities.

Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis

Vitamin E supplementation delays disease onset and slows progression in a transgenic model of familial amyotrophic lateral sclerosis, while riluzole and gabapentin prolong survival, suggesting potential therapeutic targets for oxidative damage.

Superoxide dismutase and familial amyotrophic lateral sclerosis: New insights into mechanisms and treatments

The disease in familial ALS may not result from loss of SOD1 function but rather from an adverse or novel property of the mutant SOD1 molecule, potentially involving toxic oxidative intermediates or unrelated to free radicals.

Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis

Glutathione peroxidase activity is reduced in a brain region affected in amyotrophic lateral sclerosis, suggesting free radicals may play a role in the disease's pathogenesis.

The effect of riluzole on post‐traumatic spinal cord injury in the rat

Riluzole treatment significantly improves motor function and behavior in rats with post-traumatic spinal cord injury, reducing infarct size by 53%.

Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones

Riluzole inhibits synaptic transmission presynaptically, potentially stabilizing presynaptic neurones through inhibition of voltage-activated sodium currents.

Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission

Riluzole effectively reduces quinolinate-induced neuronal damage in rats by 35%, suggesting it may be useful for treating Huntington's disease.

Citations

Pharmacological and non‐pharmacological treatments in amyotrophic lateral sclerosis: an Italian real‐world data study

Higher patient severity and complexity are associated with a lower likelihood of being treated with riluzole in newly diagnosed ALS patients in Italy.

Current Treatment Process and Challenges for Spinal Muscular Atrophy (SMA)

Current pharmacological treatments for spinal muscular atrophy include Zolgensma, Sodium vanadate, and risdiplam, while a holistic approach involving pulmonary support, nutritional supplementation, and orthopedic management is crucial for effective management.

Synthesis of 2‐Aminobenzothiazoles via Nickel‐Catalyzed Tandem Reaction of 2‐Bromophenylisothiocyante with Amines

Nickel-catalyzed tandem reaction of 2bromophenylisothiocyanate and amines efficiently synthesizes diverse 2aminobenzothiazole derivatives in good yields.

Synthesis of Hexafluoroisopropyl Aryl Ethers via Dual Photoredox/Nickel-Catalyzed C-O Coupling.

This study demonstrates a photoredox/nickel-catalyzed method for synthesis of hexafluoroisopropyl aryl ethers using a wide range of aryl and heteroaryl bromides under mild reaction conditions.

The Current Landscape of Hypotheses Describing the Contribution of CD4+ Heterogeneous Populations to ALS

The role of CD4+ T cells in ALS development is complex, with various hypotheses suggesting different CD4+ T cell populations contribute differently, potentially leading to personalized therapies.